210 related articles for article (PubMed ID: 31584764)
1. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia.
Atehortúa S; Senior JM; Castro P; Ceballos M; Saldarriaga C; Giraldo N; Mora G
Biomedica; 2019 Sep; 39(3):502-512. PubMed ID: 31584764
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
[TBL] [Abstract][Full Text] [Related]
3. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector.
Ribeiro RA; Stella SF; Camey SA; Zimerman LI; Pimentel M; Rohde LE; Polanczyk CA
Value Health; 2010; 13(2):160-8. PubMed ID: 19725912
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure.
Chen L; Hay JW
Cardiovasc Drugs Ther; 2004 Mar; 18(2):161-70. PubMed ID: 15162078
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
8. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
9. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis.
Crespo C; Linhart M; Acosta J; Soto-Iglesias D; Martínez M; Jáuregui B; Mira Á; Restovic G; Sagarra J; Auricchio A; Fahn B; Boltyenkov A; Lasalvia L; Sampietro-Colom L; Berruezo A
Eur J Prev Cardiol; 2020 Apr; 27(6):622-632. PubMed ID: 31487998
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
11. Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation.
Healy CA; Carrillo RG
Heart Rhythm; 2015 Jul; 12(7):1565-73. PubMed ID: 25839113
[TBL] [Abstract][Full Text] [Related]
12. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial.
Wilkoff BL; Boriani G; Mittal S; Poole JE; Kennergren C; Corey GR; Krahn AD; Schloss EJ; Gallastegui JL; Pickett RA; Evonich RF; Roark SF; Sorrentino DM; Sholevar DP; Cronin EM; Berman BJ; Riggio DW; Khan HH; Silver MT; Collier J; Eldadah Z; Holbrook R; Lande JD; Lexcen DR; Seshadri S; Tarakji KG
Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008503. PubMed ID: 32915063
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.
Aidelsburger P; Grabein K; Klauss V; Wasem J
Clin Res Cardiol; 2008 Feb; 97(2):89-97. PubMed ID: 17955159
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the Improve SCA study.
Higuera L; Holbrook R; Wherry K; Rodriguez DA; Cuesta A; Valencia J; Arcos J; López Gómez A
J Med Econ; 2021; 24(1):173-180. PubMed ID: 33471579
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of implantable cardioverter-defibrillators for patients who are at risk for sudden death in Argentina].
Alcaraz A; González-Zuelgaray J; Augustovski F
Value Health; 2011; 14(5 Suppl 1):S33-8. PubMed ID: 21839896
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study.
Sun H; Liu X; Fu J; Song Y; Qin X; Wang H
J Med Econ; 2024; 27(1):575-581. PubMed ID: 38566556
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
Shah D; Lu X; Paly VF; Tsintzos SI; May DM
J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
